Trump fast-tracks psychedelic research

The administration's new policy aims to relax federal restrictions on drugs such as psilocybin and LSD to spur medical research.

While some veteran groups have hailed the decision as a breakthrough for treating trauma, health experts have warned about the potential cardiac risks associated with certain psychedelics.

Trump joined Rogan in the Oval Office for the signing, signaling a significant shift in the administration's approach to emerging mental health treatments.

The order instructs the FDA to prioritize the evaluation of these substances, which could lead to a major overhaul of U.S. drug policy.